<code id='2D4F6F1769'></code><style id='2D4F6F1769'></style>
    • <acronym id='2D4F6F1769'></acronym>
      <center id='2D4F6F1769'><center id='2D4F6F1769'><tfoot id='2D4F6F1769'></tfoot></center><abbr id='2D4F6F1769'><dir id='2D4F6F1769'><tfoot id='2D4F6F1769'></tfoot><noframes id='2D4F6F1769'>

    • <optgroup id='2D4F6F1769'><strike id='2D4F6F1769'><sup id='2D4F6F1769'></sup></strike><code id='2D4F6F1769'></code></optgroup>
        1. <b id='2D4F6F1769'><label id='2D4F6F1769'><select id='2D4F6F1769'><dt id='2D4F6F1769'><span id='2D4F6F1769'></span></dt></select></label></b><u id='2D4F6F1769'></u>
          <i id='2D4F6F1769'><strike id='2D4F6F1769'><tt id='2D4F6F1769'><pre id='2D4F6F1769'></pre></tt></strike></i>

          hotspot

          hotspot

          author:knowledge    Page View:356
          accountable care organizations cost saving
          Adobe

          WASHINGTON — A key Obama-era initiative was supposed to save Medicare money by testing new policies for cutting health care costs. It has so far failed to do so, according to nonpartisan congressional budget experts, and it’s not expected to save money anytime soon.

          The 2010 Affordable Care Act created a government center, named the Center for Medicare and Medicaid Innovation, that was given $10 billion over a decade to test new Medicare and Medicaid pay policies. It has since been funded at the same level for another 10 years.

          advertisement

          Republicans have attacked the center over the years. Although most of its pilot programs involve lowering hospital spending, some of the center’s initiatives aiming to lower spending on drugs have often provoked GOP ire. Most recently, they attacked the center’s proposal to cut Medicare pay for drugs that receive accelerated approvals. The Trump administration also used pilot programs to cut drug spending, including its failed attempt to tie Medicare drug payments to prices abroad.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          FDA approval of Sarepta Duchenne genetic therapy gives me hope
          FDA approval of Sarepta Duchenne genetic therapy gives me hope

          Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

          read more
          FDA panel signals lack of confidence in Amgen cancer drug data
          FDA panel signals lack of confidence in Amgen cancer drug data

          AdobeTheclearanceofafirst-of-its-kindcancertreatmentmadebyAmgenisonshakiergroundfollowingaFoodandDru

          read more
          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more

          Obesity drug from Roche shows promise in early study

          SebastienBozon/AFPviaGettyImagesLONDON—RocheonThursdaysaiditsrecentlyacquiredexperimentalobesitymedi